Latest news from Amphivena Therapeutics on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/amphivena-therapeutics-announces-first-patient-dosed-in-the-phase-1-dose-expansion-of-amv564/?sc=rsin /articles/amphivena-therapeutics-announces-first-patient-dosed-in-the-phase-1-dose-expansion-of-amv564/?sc=rsin Wed, 16 Dec 2020 12:45:00 EST Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that depletes myeloid derived suppressor cells (MDSC) and activates T cells, in adult patients with selected solid tumor indications. Amphivena Therapeutics